{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:03:34Z","timestamp":1751947414135,"version":"3.41.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The SARS-CoV-2 pandemic disrupted healthcare systems worldwide, particularly affecting hematopoietic stem cell transplantation (HSCT) activities. Understanding the impact of the SARS-CoV-2 pandemic on transplant practices, especially in Japan, where cord blood transplantation (CBT) is prevalent, is crucial. A total of 40,444 allogeneic HSCT cases in Japan between 2011 and 2021 were examined using an interrupted time series analysis to assess the impact of COVID-19 on CBT utilization. Following the SARS-CoV-2 pandemic, CBT cases demonstrated a significant increase (11.06 [95% confidence interval (CI): 1.87 to 20.25] cases per month), whereas bone marrow transplantation cases decreased, by 10.74 cases per month (95% CI, \u221219.84 to \u22121.63 cases per month). Total HSCT cases remained stable with a level change of 5.47 cases per month (95% CI, \u221210.07 to 21.01 cases per month) and a trend change of \u22121.11 cases per month (95% CI, \u22122.22 to 0.004 cases per month). The interrupted time series analysis showed significantly increased CBT cases in Japan, highlighting its crucial role as an alternative transplant source during the pandemic. CBT offset the impact of the decrease in bone marrow transplantation and contributed to the maintenance of HSCT activity in Japan during the unprecedented crisis.<\/jats:p>","DOI":"10.1038\/s41409-025-02588-0","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:36:21Z","timestamp":1744850181000},"page":"964-970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-7777","authenticated-orcid":false,"given":"Nobuhiko","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7225-2819","authenticated-orcid":false,"given":"Tetsuji","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4599-5465","authenticated-orcid":false,"given":"Hiromi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5933-3868","authenticated-orcid":false,"given":"Motohito","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9315","authenticated-orcid":false,"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2422","authenticated-orcid":false,"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-8266","authenticated-orcid":false,"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-493X","authenticated-orcid":false,"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0823","authenticated-orcid":false,"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9104","authenticated-orcid":false,"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-9918","authenticated-orcid":false,"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2588_CR1","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(20)30854-0","volume":"395","author":"A Banerjee","year":"2020","unstructured":"Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A, Torralbo A, Shallcross L, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet. 2020;395:1715\u201325.","journal-title":"Lancet"},{"key":"2588_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907\u201318.","journal-title":"Lancet"},{"key":"2588_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1470-2045(21)00240-0","volume":"22","author":"P Ranganathan","year":"2021","unstructured":"Ranganathan P, Sengar M, Chinnaswamy G, Agrawal G, Arumugham R, Bhatt R, et al. Impact of COVID-19 on cancer care in India: a cohort study. Lancet Oncol. 2021;22:970\u20136.","journal-title":"Lancet Oncol"},{"key":"2588_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41409-022-01667-w","volume":"57","author":"MM J\u00f6ris","year":"2022","unstructured":"J\u00f6ris MM, Schmidt AH, Bernas SN, Feinberg J, Sacchi N, Elmoazzen H, et al. Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association. Bone Marrow Transpl. 2022;57:1021\u20134.","journal-title":"Bone Marrow Transpl"},{"key":"2588_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW Lee","year":"2020","unstructured":"Lee LYW, Cazier J-B, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309\u201316.","journal-title":"Lancet Oncol"},{"key":"2588_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","volume":"32","author":"P Grivas","year":"2021","unstructured":"Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu C-Y, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32:787\u2013800.","journal-title":"Ann Oncol"},{"key":"2588_CR7","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u201345.","journal-title":"Lancet Haematol"},{"key":"2588_CR8","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","volume":"35","author":"P Ljungman","year":"2021","unstructured":"Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35:2885\u201394.","journal-title":"Leukemia"},{"key":"2588_CR9","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s12185-022-03508-4","volume":"117","author":"Y Shimomura","year":"2023","unstructured":"Shimomura Y, Kitamura T, Nishikubo M, Sobue T, Uchida N, Doki N, et al. Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan. Int J Hematol. 2023;117:590\u20137.","journal-title":"Int J Hematol"},{"key":"2588_CR10","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.bbmt.2020.07.021","volume":"26","author":"G Algwaiz","year":"2020","unstructured":"Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transpl. 2020;26:2181\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2588_CR11","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1038\/s41409-020-0919-0","volume":"55","author":"P Ljungman","year":"2020","unstructured":"Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbacioglu S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transpl. 2020;55:2071\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2588_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41409-022-01604-x","volume":"57","author":"JR Passweg","year":"2022","unstructured":"Passweg JR, Baldomero H, Chabannon C, Corbacioglu S, de la C\u00e1mara R, Dolstra H, et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transpl. 2022;57:742\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"2588_CR13","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/s41409-021-01287-w","volume":"56","author":"D Russo","year":"2021","unstructured":"Russo D, Polverelli N, Malagola M, Farina M, Leoni A, Bernardi S, et al. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). Bone Marrow Transpl. 2021;56:2272\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2588_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41409-021-01477-6","volume":"57","author":"H Rafii","year":"2022","unstructured":"Rafii H, Ionescu I, Ruggeri A, Garnier F, Ballot C, Bensoussan D, et al. Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC). Bone Marrow Transpl. 2022;57:125\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2588_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ajh.25705","volume":"95","author":"T Konuma","year":"2020","unstructured":"Konuma T, Kanda J, Inamoto Y, Hayashi H, Kobayashi S, Uchida N, et al. Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. Am J Hematol. 2020;95:343\u201353.","journal-title":"Am J Hematol"},{"key":"2588_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/bmt.2009.280","volume":"44","author":"E Gluckman","year":"2009","unstructured":"Gluckman E. History of cord blood transplantation. Bone Marrow Transpl. 2009;44:621\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2588_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3\u201310.","journal-title":"Int J Hematol"},{"key":"2588_CR18","first-page":"348","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46:348\u201355.","journal-title":"Int J Epidemiol"},{"key":"2588_CR19","doi-asserted-by":"publisher","first-page":"e003567","DOI":"10.1136\/bmjgh-2020-003567","volume":"5","author":"C Hategeka","year":"2020","unstructured":"Hategeka C, Ruton H, Karamouzian M, Lynd LD, Law MR. Use of interrupted time series methods in the evaluation of health system quality improvement interventions: a methodological systematic review. BMJ Glob Health. 2020;5:e003567. https:\/\/doi.org\/10.1136\/bmjgh-2020-003567.","journal-title":"BMJ Glob Health"},{"key":"2588_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/ije\/dyaa148","volume":"50","author":"H Xiao","year":"2021","unstructured":"Xiao H, Augusto O, Wagenaar BH. Reflection on modern methods: a common error in the segmented regression parameterization of interrupted time-series analyses. Int J Epidemiol. 2021;50:1011\u20135.","journal-title":"Int J Epidemiol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02588-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02588-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02588-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:06:06Z","timestamp":1751857566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02588-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2588"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02588-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NN received honoraria from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Sanofi, Novartis, MSD K.K., Sumitomo Pharma Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Meiji Seika Pharma Co., Ltd., and AstraZeneca K.K. HN received honoraria from Janssen Pharma and a scholarship from JCR Pharmaceuticals. NU received honoraria from Otsuka Pharmaceutical Co., Ltd., and AbbVie GK; research funding from Astellas Pharma Inc.; and scholarships from Chugai Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Kyowa Kirin Co., Ltd. TT received honoraria from Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., and Bristol-Myers Squibb Co.; research funding from Astellas Pharma Inc., LUCA Science Inc., Otsuka Pharmaceutical Co., Ltd., Priothera SAS, PharmaEssentia Japan K.K., AbbVie GK, IQVIA Services Japan GK, Kyowa Kirin Co., Ltd., CMIC Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb Co., Janssen Pharma, and CSL Behring K.K.; scholarships from Asahi Kasei Pharma Corp., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; and support for an endowed chair from the International Advanced Medical Organization. The remaining authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Data Management Committee of the JDCHCT and the Medical Review Board of Gifu University Graduate School of Medicine (#2023-305). Written informed consent was obtained from all participants before registration in TRUMP 2. All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki and its later amendments. No identifiable images or other personal details of participants are presented in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}